 CAMBRIDGE, Mass.--BUSINESS WIRE--Magenta Therapeutics NASDAQ: MGTA and bluebird bio, Inc. NASDAQ: BLUE today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease SCD. The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patien 